Definitive Contract 75N92020C00014
Award Date 7/30/20
Potential Completion Date 5/4/24
Potential Value $25M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $6,250,000.00 firm fixed-price definitive contract awarded by the National Heart Lung and Blood Institute, a civilian agency, to Meridian Bioscience Inc., a foreign-owned, for-profit manufacturer of in vitro diagnostic test kits and medical testing technologies. The contract is for the Rapid Acceleration of Diagnostics (RADx) Tech Project #6139, which involves the supply of Meridian Bioscience's RevogeneⓇ SARS-CoV-2 assay. This diagnostic test is being procured to support the...
- The U.S. National Institute of Biomedical Imaging and Bioengineering, part of the Department of Health and Human Services, awarded a $16,239,965.00 firm fixed price contract to Mologic Inc., a foreign-owned for-profit organization, for the Rapid Acceleration of Diagnostics (RADx) Program Tech Project #7697: SARS-CoV-2 Antigen Home Test. This contract, which does not have a set-aside designation, aims to deliver the testing products through January 2025 from Mologic's facility in Bedford, New...
- The National Heart, Lung, and Blood Institute awarded a $3.75 million firm fixed-price definitive contract to Avantgen Inc. on November 22, 2021, to develop a highly sensitive rapid test kit for SARS-CoV-2 that does not require a reader device under the Rapid Acceleration of Diagnostics (RADx) program. The contract, which extended through September 29, 2023, is being performed in San Diego, California. No set-aside designation was used for this award. The RADx program, a coordinated federal...
- This is a $5,240,000.00 firm fixed price definitive contract awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Lumiradx, Inc., a foreign-owned, for-profit organization. The contract is for Lumiradx to provide a SARS-CoV-2 & Flu A/B high sensitivity antigen assay under the RADX Tech program. The contract has an ultimate completion date of May 31, 2022 and was awarded on September 30, 2021. This contract is not associated with any set-aside designation.
- The National Institutes of Health (NIH) awarded a $92,645,361.50 firm-fixed-price contract to Quidel Corporation to provide rapid COVID-19 antigen test kits under the Rapid Acceleration of Diagnostics (RADx) initiative. The contract, which does not have a set-aside designation, runs through April 30, 2025 and requires Quidel to deliver the tests from its facilities in San Diego, California. Quidel is a manufacturer of medical diagnostics and supplies, and has received numerous federal...
- Minute Molecular Diagnostics, Inc. was awarded a definitive, firm fixed price contract valued at seventeen million, five hundred ninety thousand dollars by the Department of Health and Human Services' National Institutes of Health National Heart, Lung and Blood Institute. The contract is for the RADX TECH PROJECT 2200 to develop a high-throughput, fast-turnaround, field-deployable COVID-19 molecular diagnostic system. Work will be performed in Evanston, Illinois with a period of performance...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded an $18.2 million firm fixed price definitive contract to Quanterix Corporation as part of the Rapid Acceleration of Diagnostics initiative. The RADx program aims to expedite the development, commercialization, and implementation of Covid-19 testing technologies to significantly increase domestic testing capacity. Quanterix will support this objective through the delivery of diagnostic solutions over a two-year...
- This $34,714,763.00 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Detect Inc. to advance the development of a second-generation, multi-analyte molecular SARS-CoV-2 and influenza A/B test that has a reduced time to result and increased sensitivity for use at home or in a point-of-care setting. The contract is not set aside. The award references a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research...
- The Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $12.5 million firm fixed-price purchase order to Mesa Biotech, Inc. for the development of the Accula Flu/SARS-CoV-2 Integrated Test. The contract supports the national interest of responding to the coronavirus COVID-19 pandemic through the development of an integrated diagnostic test for influenza and SARS-CoV-2. Performance will take place in San Diego, California over one...
- Flambeau Diagnostics LLC was awarded a definitive firm fixed-price contract valued at $22.57 million by the National Heart, Lung, and Blood Institute (NHLBI) on July 1, 2021, for the development of point-of-need, saliva-based COVID-19 testing platforms under the RADX Tech 2375 program. The contract was performed in Madison, Wisconsin, with an ultimate completion date of March 31, 2023. This award did not utilize a set-aside designation and represents a civilian agency procurement for critical...